BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...data YE19 Retrophin Inc. (NASDAQ:RTRX) Fosmetpantotenate Treat pantothenate kinase-associated neurodegeneration (PKAN) Phase III data 3Q19 Revogenex Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...4/29/19 Revance Therapeutics Inc. (NASDAQ:RVNC) DaxibotulinumtoxinA Treat moderate to severe glabellar lines Submit BLA 2Q19 Revogenex Inc....
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...metastatic melanoma PDUFA date 6/30/18 Avenue Therapeutics Inc. (NASDAQ:ATXI) / Fortress Biotech Inc. (NASDAQ:FBIO) / Revogenex Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...III TACTT3 data Early 2018 Avenue Therapeutics Inc. (NASDAQ:ATXI) / Fortress Biotech Inc. (NASDAQ:FBIO) / Revogenex Inc....
BioCentury | Apr 6, 2015
Analyst Picks & Changes

Analyst picks & changes

...innovative products and technologies with long-term potential. He highlighted IV tramadol, which Coronado in-licensed from Revogenex Inc....
BioCentury | Mar 9, 2015
Company News

Revogenex, Coronado Biosciences deal

...which will focus on developing and commercializing products for use in the U.S. hospital market. Revogenex...
...to initiate Phase III trials of the synthetic opioid to treat postoperative pain this year. Revogenex Inc....
Items per page:
1 - 6 of 6
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...data YE19 Retrophin Inc. (NASDAQ:RTRX) Fosmetpantotenate Treat pantothenate kinase-associated neurodegeneration (PKAN) Phase III data 3Q19 Revogenex Inc....
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...4/29/19 Revance Therapeutics Inc. (NASDAQ:RVNC) DaxibotulinumtoxinA Treat moderate to severe glabellar lines Submit BLA 2Q19 Revogenex Inc....
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...metastatic melanoma PDUFA date 6/30/18 Avenue Therapeutics Inc. (NASDAQ:ATXI) / Fortress Biotech Inc. (NASDAQ:FBIO) / Revogenex Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...III TACTT3 data Early 2018 Avenue Therapeutics Inc. (NASDAQ:ATXI) / Fortress Biotech Inc. (NASDAQ:FBIO) / Revogenex Inc....
BioCentury | Apr 6, 2015
Analyst Picks & Changes

Analyst picks & changes

...innovative products and technologies with long-term potential. He highlighted IV tramadol, which Coronado in-licensed from Revogenex Inc....
BioCentury | Mar 9, 2015
Company News

Revogenex, Coronado Biosciences deal

...which will focus on developing and commercializing products for use in the U.S. hospital market. Revogenex...
...to initiate Phase III trials of the synthetic opioid to treat postoperative pain this year. Revogenex Inc....
Items per page:
1 - 6 of 6